Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119138) titled 'The Efficacy and Safety of Imatinib in Treating Refractory Alopecia Areata: A Prospective, Single-Arm, Exploratory Study' on Feb. 24.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Xiangya Hospital, Central South University

Condition: Alopecia areata

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-03-09

Target Sample Size: Experimental group:60;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=309868

Disclaimer: Curated by HT Syndication....